Acyclovir Capsule
Product Images NDC 71205-578

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Acyclovir (NDC 71205-578). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-578-30 (6144211401)

This is a description of Acyclovir, a prescription drug that comes in the form of capsules containing 200mg of Acyclovir USP. It is packaged by Proficent Rx LP with the product ID QA057830. Each capsule is an oval shape, and has an opaque light blue cap imprinted with the number "200" and an aqua blue opaque body imprinted with the letters "CTI" over "114". The lot number is mentioned as 00000, and the expiration date is 00/00/00. The product is intended for use by individuals with a valid prescription only, and should be kept out of the reach of children.*

FDA Label Image

Structural Formula (Acy03 0000 01)

FDA Label Image

Table 1 (Acy03 0000 02)

Table 1 provides pharmacokinetic features of Acyclovir including plasma protein binding, plasma elimination half-life, and average oral bioavailability. The range of values is given for each parameter. The plasma protein binding ranges from 9% to 1033%, while the half-life of plasma elimination ranges from 25 to 1033 hours. The average oral bioavailability ranges from 10% to 20%, with a decrease in bioavailability observed for higher doses.*

FDA Label Image

Table 2 (Acy03 0000 03)

This text provides the Acyclovir peak and trough concentrations at a steady-state for three different dosages: 200mg, 400mg, and 800mg. The concentrations are given in meg/mL.*

FDA Label Image

Table 3 (Acy03 0000 04)

Table 3 shows the adjusted dosage regimen for individuals suffering from renal impairment. The table contains information on the normal dosage, creatinine clearance, and adjusted dosage regimen. The adjusted dosage regimen is based on the severity of the impairment and ranges from 200 mg to 800 mg, administered every 4 to 12 hours. Dosage is adjusted depending on the patient's creatinine clearance levels.*

FDA Label Image

Imprint Cti 114 (Acy03 0000 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.